Announcement Summary

Entity name

MAYNE PHARMA GROUP LIMITED

Date of this announcement

Friday May 05, 2023

The +securities the subject of this notification are:

☑ +Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends

Total number of +securities to be issued/transferred

ASX +security code	Security description	Total number of +securities to be issued/transferred	Issue date
MYXAN	PERFORMANCE RIGHTS	917,873	16/03/2023

Refer to next page for full details of the announcement

Part 1 - Entity and announcement details

1.1 Name of entity

MAYNE PHARMA GROUP LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type

ABN

Registration number

76115832963

1.3 ASX issuer code

MYX

1.4 The announcement is

☑ New announcement

1.5 Date of this announcement

5/5/2023

Part 2 - Issue details

2.1 The +securities the subject of this notification are:

☑ +Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

☑ has an existing ASX security code ("existing class")

Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

Additional +securities in an existing class issued under an +employee incentive scheme

ASX +security code and description

MYXAN : PERFORMANCE RIGHTS

Date the +securities the subject of this notification were issued

16/3/2023

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class

☑ Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

☑ Yes

Provide details of the KMP or +associates being issued +securities.

Name of KMP	Name of registered holder	Number of +securities
Aaron Gray	Aaron Gray	145,641

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

- Rights are eligible for vesting on 1 September 2025, subject to achievement of specific vesting condition hurdles.
- The number / proportion of Rights that vest is based on the absolute Total Shareholder Return (TSR) over the period with 20% vesting if a TSR Compound Annual Growth (CAGR) of 8% is achieved, rising to 100% vesting for achievement of a TSR CAGR of 15%.

Any other information the entity wishes to provide about the +securities the subject of this notification

- The base test date for Rights is set as 1 September 2022 and the expiry date is 30 September 2027
- The Base Test Price for the Rights is $3.51.
- If the Rights are not exercised before the expiry date they will automatically lapse.
- There are no voting rights or rights to dividends whilst the participant holds a Right.

Issue details

Number of +securities

917,873

Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this application, the +securities of the entity will comprise:
(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

4.1 Quoted +Securities (Total number of each +class of +securities quoted)

ASX +security code and description	Total number of +securities on issue
MYX : ORDINARY FULLY PAID	85,074,288

4.2 Unquoted +Securities (Total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
MYXAA : CONVERTIBLE NOTES	27,950
MYXAN : PERFORMANCE RIGHTS	3,860,680
MYXAT : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	835,338

Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?

☑ No

5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?

☑ No

5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

☑ Yes

5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

917,873

5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?

☑ No